维普期刊资源整合服务平台（V6.5）

125篇 您的检索式：作者名="de Bono JS"

选中清除导出查看参考文献查看引证文献引用追踪共7页首页上一页第1页下一页末页 /7 跳转

	题名	作者	年代	出处	被引量
1	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer 显示文摘	de Bono JS Seller HI Montgomery RB	2008	Clin Cancer Res2008，14，19：	1
2	Personalization of prostate cancer pre- vention and therapy:are clinically qualified biomarkers in the horizon显示文摘	Yap TA Swantan C de Bono JS	2012	EPMA J2012，3，1：	1
3	Circulatingtumor cells predict survival benefit from treatment in metastaticcastration-resistant prostate cancer显示文摘	de Bono JS Scher HI Montgomery RB	2008	Clin Cancer Res2008，14，19：	1
4	Circulating tumour cells as prognostic markers in progressive, castration- resistant prostate cancer: a reanalysis of IMMC38 trial data显示文摘	Scher HI Jia X de Bono JS	2009	Lancet Oncol2009，10，3：	1
5	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer显示文摘	de Bono JS Scher HI Montgomery RB	2008	Clin Cancer Res2008，14，：	1
6	Therapeutic options for advanced prostatecancer: 2011 update显示文摘	Omlin A de Bono JS	2012	Curr Urol Rep2012，13，2：	1
7	Belinostat: clinical applications in solid tumors and lymphoma显示文摘	Molife LR De Bono JS	2011	Expert Opin lnvestig Drugs2011，20，12：	1
8	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer 显示文摘	de Bono JS Scher HI Montgomery RB	2008	Clin Cancer Res2008，14，19：	1
9	Anti-tumor activity of abi- raterone acetate ( AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer ( CRPC ) 显示文摘	De Bono JS Attm'd G Reid AH	2008	J Clin Oncol2008，，：	1
10	First in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors显示文摘	De Bono JS Mina LA Gonzalez M	2013	J Clin Oncol2013，，：	1
11	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer显示文摘	de Bono JS Scher HI Montgomery RB	2008	Clin Cancer Res2008，14，19：	1
12	Prednisone plus caba- zitaxcl or mitoxantrone for metastatic castration-resistant pros-tate cancer progressing after docetaxel treatment: a randomized open-label trial 显示文摘	de Bono JS Oudard S Ozguroglu M	2010	Lancet2010，376，9747：	1
13	Abiraterone and in- creased survival in metastatic prostate cancer 显示文摘	de Bono JS Logothetis C J Molina A	2011	N Engl J Med2011，364，19：	1
14	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment : a randomised open-label trim 显示文摘	de Bono JS Oudard S Ozguroglu M	2010	Lancet2010，376，9747：	1
15	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer显示文摘	de Bono JS Sober HI Montgomery RB	2008	Clin Cancer Res2008，14，19：	1
16	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial显示文摘	de Bono JS Oudard S Ozguroglu M	2010	Lancet2010，376，9747：	1
17	predictive biomarkers for targeting insulin-like growth factor-1 (IGF-1)receptor显示文摘	Carden CP Molife LR de Bono JS		0，，08：	1
18	Utilizing circulating tumor cells:challenges and pitfalls显示文摘	Attard G de Bono JS	2011	Curr Opin Genet Dev2011，21，1：	1
19	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer显示文摘	de Bono JS Scher HI Montgomery RB	2008	Clin Cancer Res2008，14，19：	1
20	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer显示文摘	de Bono JS Scher HI Montgomery RB	2008	Clin Cancer Res2008，14，19：	1

返回顶部每页显示：

共7页首页上一页第1页下一页末页 /7 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示